Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.
Thakur MK, Heilbrun LK, Sheng S, Stein M, Liu G, Antonarakis ES, Vaishampayan U, Dzinic SH, Li X, Freeman S, Smith D, Heath EI. Thakur MK, et al. Among authors: heath ei. Invest New Drugs. 2016 Feb;34(1):112-8. doi: 10.1007/s10637-015-0307-6. Epub 2015 Nov 18. Invest New Drugs. 2016. PMID: 26581400 Free PMC article. Clinical Trial.
Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma.
Heath EI, Burtness BA, Kleinberg L, Salem RR, Yang SC, Heitmiller RF, Canto MI, Knisely JP, Topazian M, Montgomery E, Tsottles N, Pithavala Y, Rohmiller B, Collier M, Forastiere AA. Heath EI, et al. Invest New Drugs. 2006 Mar;24(2):135-40. doi: 10.1007/s10637-006-5934-5. Invest New Drugs. 2006. PMID: 16502351 Clinical Trial.
New targets in the management of prostate cancer.
Heath EI, Carducci MA. Heath EI, et al. Hematol Oncol Clin North Am. 2006 Aug;20(4):985-99, xi. doi: 10.1016/j.hoc.2006.05.001. Hematol Oncol Clin North Am. 2006. PMID: 16861127 Review.
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Gadgeel SM, Ruckdeschel JC, Heath EI, Heilbrun LK, Venkatramanamoorthy R, Wozniak A. Gadgeel SM, et al. Among authors: heath ei. J Thorac Oncol. 2007 Apr;2(4):299-305. doi: 10.1097/01.JTO.0000263712.61697.69. J Thorac Oncol. 2007. PMID: 17409801 Free article. Clinical Trial.
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors.
Lorusso P, Heath EI, McGreivy J, Sun YN, Melara R, Yan L, Malburg L, Ingram M, Wiezorek J, Chen L, Pilat MJ. Lorusso P, et al. Among authors: heath ei. Invest New Drugs. 2008 Oct;26(5):455-62. doi: 10.1007/s10637-008-9144-1. Epub 2008 Jun 24. Invest New Drugs. 2008. PMID: 18574557 Clinical Trial.
233 results